Optimizing Outcomes in Allogeneic Transplants - Episode 8
Emerging Cellular Therapies in Hematologic Malignancies
An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.
This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.
The panel discusses the 2 main directions in allogeneic stem cell transplantation: drug development and graft engineering. Drug development focuses on improving graft-vs-host disease (GVHD) prophylaxis and treatment, while graft engineering explores strategies for T-cell depletion and manipulation.
Graft engineering approaches include improving CD34 selection, using T-cell receptor ⍺/ß depletion, and CD45RA depletion. The ongoing Orca-T trial, which adds regulatory T cells and conventional T cells to a CD34-selected graft, has shown promising results in preventing GVHD.
The panel emphasizes the importance of educating transplant physicians and patients about these advances, with resources like BMT InfoNet providing information on graft manipulation. The National Marrow Donor Program plays a crucial role in facilitating unrelated donor stem cell donation for graft manipulation at central facilities.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.